ReviewInternational journal of nanomedicine2026
Research Progress on Nano-Drug Delivery Systems for Photothermal Cancer Therapy.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanostructured lipid carriers as co-delivery systems for cancer therapy: Prospects and challenges.International journal of pharmaceutics: X · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains one of the most formidable challenges in modern medicine. To mitigate the systemic toxicity associated with conventional therapies such as radiotherapy and chemotherapy, photothermal therapy (PTT) has emerged as a highly promising adjuvant modality. The efficacy of PTT hinges on photothermal agents (PTAs), typically nanomaterials that convert light energy into localized hyperthermia to ablate cancer cells. The convergence of nanotechnology and drug delivery has provided a robust platform for PTT, enabling its integration with other therapeutic modalities to enhance efficacy and reduce side effects. This review constructs a three-dimensional analytical framework based on the "carrier-function-application" paradigm, systematically evaluating four major nanocarrier families: lipids, polymers, proteins, and biomimetics. We critically analyze the unique advantages and challenges of each carrier type when delivering various PTAs and further explore multimodal combination therapy strategies. By synthesizing cutting-edge research, we distill key design principles: the core of an efficient photothermal nanosystem lies in overcoming bottlenecks such as poor tumor targeting and heterogeneous tumor microenvironments through intelligent responsive design and biomimetic modification. This framework provides a clear theoretical basis and practical pathway for developing next-generation PTT platforms characterized by high efficiency, safety, and strong clinical translation potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.